Idorsia Ltd (SWX:IDIA)
3.675
-0.035 (-0.94%)
Oct 22, 2025, 9:06 AM CET
Idorsia Revenue
Idorsia had revenue of 72.24M CHF in the quarter ending June 30, 2025, with 341.89% growth. This brings the company's revenue in the last twelve months to 217.22M, up 69.92% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
217.22M
Revenue Growth
+69.92%
P/S Ratio
3.94
Revenue / Employee
334.19K
Employees
650
Market Cap
855.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Idorsia News
- 12 days ago - Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability - GlobeNewsWire
- 12 days ago - Idorsia launches an offering of registered shares – to fund the company to overall profitability - GlobeNewsWire
- 4 weeks ago - Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China - GlobeNewsWire
- 4 weeks ago - Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension - Benzinga
- 4 weeks ago - Idorsia's JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension - GlobeNewsWire
- 5 weeks ago - Idorsia Ltd (IDRSF) Special Call - Slideshow - Seeking Alpha
- 5 weeks ago - Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 - GlobeNewsWire
- 6 weeks ago - Idorsia Ltd (IDRSF) TRYVIO Investor Q&A Webcast And Conference Call (Transcript) - Seeking Alpha